Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Bristol-Myers Squibb Co's interest expense for the
three
months ended in Mar. 2026 was ARS -574,679 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was ARS-2,429,376 Mil.
Bristol-Myers Squibb Co (BUE:BMY) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Bristol-Myers Squibb Co's Interest Expense for the
three
months ended in Mar. 2026 was ARS-574,679 Mil. Its
Operating Income
for the
three
months ended in Mar. 2026 was ARS4,705,095 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2026 was ARS61,413,721 Mil.
Bristol-Myers Squibb Co's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Bristol-Myers Squibb Co Interest Expense Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS-2,429,376 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Expense of ARS-2,429,376 Mil mean?
Bristol-Myers Squibb Co (BUE:BMY) has a Interest Expense of ARS-2,429,376 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Bristol-Myers Squibb Co and its competitors.
Is Bristol-Myers Squibb Co's Interest Expense too high?
Bristol-Myers Squibb Co's current Interest Expense is ARS-2,429,376 Mil. Overall, Bristol-Myers Squibb Co has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Interest Expense compare to PFE and GILD?
Bristol-Myers Squibb Co's Interest Expense of ARS-2,429,376 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current Interest Expense is ARS-2,429,376 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (BUE:BMY) is currently considered Fairly Valued. The stock's GF Value™ is ARS28,041.85, compared to a current price of ARS29,480.00 — trading 5.1% above its estimated fair value. The current Interest Expense is ARS-2,429,376 Mil. Bristol-Myers Squibb Co's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Bristol-Myers Squibb Co (BUE:BMY), the current Interest Expense is ARS-2,429,376 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (BUE:BMY) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of ARS29,480.00 is trading 5.1% above its estimated GF Value™ of ARS28,041.85.
GuruFocus considers Bristol-Myers Squibb Co to be Fairly Valued.
Key valuation signals for BUE:BMY:
Interest Expense: ARS-2,429,376 Mil
GF Value™: ARS28,041.85 vs. price of ARS29,480.00 (5.1% above fair value)
No single metric tells the full story. See the BUE:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
55GF Score
Get the complete analysis for BUE:BMY
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:BMY has been successfully added to your 
